Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
aldosterone
blood pressure
ejection fraction
eplerenone
heart failure
mineralocorticoid receptor
spironolactone
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
20
06
2019
revised:
09
09
2019
accepted:
10
09
2019
pubmed:
14
1
2020
medline:
4
3
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
The purpose of this study was to investigate the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes according to baseline SBP in patients with heart failure with reduced ejection fraction (HFrEF). MRAs are greatly underused in patients with HFrEF, often because of fear of adverse events. Concern about hypotension has been raised by the demonstration that MRAs are particularly effective treatment for resistant hypertension. The effect of MRA therapy was studied in 4,396 patients with HFrEF randomized in the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials. Mean SBP change from baseline to 6 months was +1.4 ± 18.1 mm Hg in the placebo group and -1.2 ± 17.9 mm Hg in the MRA group. The between-treatment difference was 2.6 mm Hg (95% confidence interval [CI]: 1.5 to 3.6; p < 0.001). All outcomes were reduced by MRA therapy overall, with consistent effects across SBP categories (e.g., all-cause mortality, overall hazard ratio [HR] of 0.72; 95% CI: 0.64 to 0.82; p < 0.001; SBP ≤105 mm Hg; HR: 0.72; 95% CI: 0.56 to 0.94; SBP >105 to ≤115 mm Hg; HR: 0.78; 95% CI: 0.60 to 1.02; SBP >115 to ≤125 mm Hg; HR: 0.71; 95% CI: 0.53 to 0.94; SBP >125 to ≤135 mm Hg; HR: 0.79; 95% CI: 0.57 to 1.10; and SBP > 135 mm Hg; HR: 0.67; 95% CI: 0.50 to 0.90; p for interaction = 0.95). Hypotension was infrequent and not more common with MRA therapy than with placebo, overall (4.6% vs. 3.9%; p = 0.25) or in any SBP category. MRA treatment had little effect on SBP in patients with HFrEF, and the clinical benefits were not modified by baseline SBP. MRA treatment infrequently caused hypotension, even when the baseline SBP was low. The treatment discontinuation rates between MRA and placebo therapy were similar. Low SBP is not a reason to withhold MRA therapy in patients with HFrEF.
Sections du résumé
OBJECTIVES
The purpose of this study was to investigate the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes according to baseline SBP in patients with heart failure with reduced ejection fraction (HFrEF).
BACKGROUND
MRAs are greatly underused in patients with HFrEF, often because of fear of adverse events. Concern about hypotension has been raised by the demonstration that MRAs are particularly effective treatment for resistant hypertension.
METHODS
The effect of MRA therapy was studied in 4,396 patients with HFrEF randomized in the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials.
RESULTS
Mean SBP change from baseline to 6 months was +1.4 ± 18.1 mm Hg in the placebo group and -1.2 ± 17.9 mm Hg in the MRA group. The between-treatment difference was 2.6 mm Hg (95% confidence interval [CI]: 1.5 to 3.6; p < 0.001). All outcomes were reduced by MRA therapy overall, with consistent effects across SBP categories (e.g., all-cause mortality, overall hazard ratio [HR] of 0.72; 95% CI: 0.64 to 0.82; p < 0.001; SBP ≤105 mm Hg; HR: 0.72; 95% CI: 0.56 to 0.94; SBP >105 to ≤115 mm Hg; HR: 0.78; 95% CI: 0.60 to 1.02; SBP >115 to ≤125 mm Hg; HR: 0.71; 95% CI: 0.53 to 0.94; SBP >125 to ≤135 mm Hg; HR: 0.79; 95% CI: 0.57 to 1.10; and SBP > 135 mm Hg; HR: 0.67; 95% CI: 0.50 to 0.90; p for interaction = 0.95). Hypotension was infrequent and not more common with MRA therapy than with placebo, overall (4.6% vs. 3.9%; p = 0.25) or in any SBP category.
CONCLUSIONS
MRA treatment had little effect on SBP in patients with HFrEF, and the clinical benefits were not modified by baseline SBP. MRA treatment infrequently caused hypotension, even when the baseline SBP was low. The treatment discontinuation rates between MRA and placebo therapy were similar. Low SBP is not a reason to withhold MRA therapy in patients with HFrEF.
Identifiants
pubmed: 31926854
pii: S2213-1779(19)30802-9
doi: 10.1016/j.jchf.2019.09.011
pmc: PMC7086149
pii:
doi:
Substances chimiques
Mineralocorticoid Receptor Antagonists
0
Spironolactone
27O7W4T232
Eplerenone
6995V82D0B
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-198Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Références
Eur J Heart Fail. 2017 Oct;19(10):1284-1293
pubmed: 28580625
J Am Coll Cardiol. 2008 Dec 9;52(24):2000-7
pubmed: 19055992
Am J Hypertens. 2018 Mar 10;31(4):407-414
pubmed: 29228101
Eur Heart J. 2017 Apr 14;38(15):1132-1143
pubmed: 28158398
Eur J Heart Fail. 2010 Jun;12(6):617-22
pubmed: 20388647
Cardiovasc Ther. 2018 Oct;36(5):e12459
pubmed: 30019390
Eur Heart J. 2008 Jul;29(14):1739-52
pubmed: 18506054
Eur J Heart Fail. 2018 Sep;20(9):1326-1334
pubmed: 29578280
Am Heart J. 2013 Feb;165(2):216-25
pubmed: 23351825
J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9
pubmed: 15093878
Am J Cardiol. 1998 Oct 15;82(8):961-5
pubmed: 9794352
Circ Heart Fail. 2008 May;1(1):34-42
pubmed: 19808268
Heart Fail Rev. 2013 Mar;18(2):107-22
pubmed: 22581217
N Engl J Med. 1999 Sep 2;341(10):709-17
pubmed: 10471456
Lancet. 2015 Nov 21;386(10008):2059-2068
pubmed: 26414968
Eur J Heart Fail. 2014 Jul;16(7):810-6
pubmed: 24961493
N Engl J Med. 2011 Jan 6;364(1):11-21
pubmed: 21073363
Lancet. 1999 Jan 2;353(9146):9-13
pubmed: 10023943
Eur Heart J. 1995 Dec;16 Suppl N:107-10
pubmed: 8682055
J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93
pubmed: 23810881
Lancet. 2003 Sep 6;362(9386):772-6
pubmed: 13678870